Prognostic significance of CYFRA 21-1 in non-small cell lung cancer

被引：0
|
作者：
Hirashima, T
Takada, M
Komiya, T
Nitta, T
Masashi, K
Masuda, N
Matui, K
Kikui, M
Yasumitsu, T
Kawase, I
机构：
[1] Osaka Prefectural Habikino Hosp, Dept Internal Med, Habikino, Osaka 5838588, Japan
[2] Osaka Prefectural Habikino Hosp, Dept Surg, Habikino, Osaka 5838588, Japan
[3] Osaka Prefectural Habikino Hosp, Dept Pathol, Habikino, Osaka 5838588, Japan
[4] Izumisano Municipal Hosp, Div Resp, Izumisano, Osaka 5988577, Japan
来源：
ANTICANCER RESEARCH | 1998年 / 18卷 / 6B期
关键词：
non-small cell lung cancer; CYFRA; 21-1; prognostic factor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Between July 1991 and February 1993, CYFRA 21-1 levels of 149 newly diagnosed patients with histologically proven non-small cell lung cancer (NSCLC) at Osaka Prefectural Habikino Hospital were measured with an enzyme immunoassay method developed by Boeringer Mannheim (Enzymum-Test CYFRA 21-1). NSCLC patients with CYFRA 21-1 serum levels over 3.5 ng/ml had a significantly poorer prognosis than did patients with normal CYFRA 21-1 levels (P<0.001). Univariate analysis revealed that CYFRA 21-1 levels above 3.5 ng/ml, poor PS, advanced stage and serum LDH over 450U/l strongly correlated with survival period. In multivariate analysis, however, only CYFRA 21-1 was found to be an independent prognostic factor compatible with Stage and PS (P=0.0040 for CYFRA 21-1, P<0.001 for PS, P=0.0052 for Stage).
引用
收藏
页码：4713 / 4716
页数：4
相关论文
共 50 条
  • [21] Predictive role of CYFRA 21-1 for S-1 monotherapy in non-small cell lung cancer patients
    Kagawa, Yusuke
    Sone, Kazuki
    Oguri, Tetsuya
    Horiuchi, Minoru
    Fukuda, Satoshi
    Uemura, Takehiro
    Takakuwa, Osamu
    Maeno, Ken
    Fukumitsu, Kennsuke
    Kanemitsu, Yoshihiro
    Tajiri, Tomoko
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Ito, Yutaka
    Niimi, Akio
    [J]. RESPIRATORY INVESTIGATION, 2022, 60 (03) : 393 - 399
  • [22] CYFRA 21-1 and CEA as prognostic factors in operated stage I non small cell lung cancer patients?
    Blankenburg, Florian
    Hatz, Rudolf
    Nagel, Dorothea
    Reinmiedl, Judith
    Seidel, Dietrich
    Stieber, Petra
    [J]. TUMOR BIOLOGY, 2007, 28 : 74 - 74
  • [23] Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
    Jung, Minkyu
    Kim, Se Hyun
    Lee, Young Joo
    Hong, Soojung
    Kang, Young Ae
    Kim, Se Kyu
    Chang, Joon
    Rha, Sun Young
    Kim, Joo Hang
    Kim, Dae Joon
    Cho, Byoung Chul
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, 2 (04) : 685 - 693
  • [24] CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy
    Ebert, W
    Muley, T
    [J]. ANTICANCER RESEARCH, 1999, 19 (4A) : 2669 - 2672
  • [25] Serum CYFRA 21-1 as a prognostic marker in lung cancer
    Pujol, JL
    Grenier, J
    Pujol, H
    Michel, EB
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1256 - 1256
  • [26] Is CYFRA 21-1 and CEA estimation helpful in preoperative assessment of non-small cell lung cancer (NSCLC) patients?
    Monika, Szturmowicz
    Ski, Rudzi P.
    Kacprzak, A.
    Langfort, R.
    Demkow, U.
    Bestry, I
    Orlowski, T.
    [J]. TUMOR BIOLOGY, 2006, 27 : 79 - 79
  • [27] Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer
    Nakao, Makoto
    Kinoshita, Ryosuke
    Kuriyama, Mamiko
    Kiyotoshi, Hiroko
    Sugihara, Masahiro
    Takeda, Norihisa
    Ohtakara, Kazuhiro
    Muramatsu, Hideki
    [J]. ANTICANCER RESEARCH, 2024, 44 (02) : 845 - 851
  • [28] Serum CYFRA 21-1 as a biomarker of pemetrexed plus cisplatin treatment in nonsquamous non-small cell lung cancer
    Sakatani, Toshio
    Ohyanagi, Fumiyoshi
    Tanimoto, Azusa
    Kawano, Yuko
    Saito, Ryota
    Kaburaki, Kyohei
    Yanagitani, Noriko
    Kudo, Keita
    Horiike, Atsushi
    Hagiwara, Sachiko
    Horai, Takeshi
    Nishio, Makoto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
    Sone, Kazuki
    Oguri, Tetsuya
    Nakao, Makoto
    Kagawa, Yusuke
    Kurowaka, Ryota
    Furuta, Hiromi
    Fukuda, Satoshi
    Uemura, Takehiro
    Takakuwa, Osamu
    Kanemitsu, Yoshihiro
    Ohkubo, Hirotsugu
    Takemura, Masaya
    Maeno, Ken
    Ito, Yutaka
    Sato, Hidefumi
    Muramatsu, Hideki
    Niimi, Akio
    [J]. ANTICANCER RESEARCH, 2017, 37 (02) : 935 - 939
  • [30] Diagnostic and Prognostic Significance of Serum Biomarkers - Serum Amyloid A and CYFRA 21-1 in Lung Cancer
    Dhanurdhar, Yera
    Jagaty, Suman Kumar
    Subhankar, Saswat
    Behera, Debasis
    [J]. INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2023, 13 (02) : 89 - 94
12345